Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Depemokimab in severe eosinophilic asthma
NCT05243680Phase 3Completed
- Sponsor
- GSK
- Start
- Mar 2022
- Primary completion
- May 2025
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 3 trial of depemokimab in asthma, sponsored by GSK. Started Mar 2022; status: completed.
02
Drugs
depemokimab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05243680.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05243680.